ATE126535T1 - ''walk-through''-mutagenese. - Google Patents

''walk-through''-mutagenese.

Info

Publication number
ATE126535T1
ATE126535T1 AT91908402T AT91908402T ATE126535T1 AT E126535 T1 ATE126535 T1 AT E126535T1 AT 91908402 T AT91908402 T AT 91908402T AT 91908402 T AT91908402 T AT 91908402T AT E126535 T1 ATE126535 T1 AT E126535T1
Authority
AT
Austria
Prior art keywords
antibodies
libraries
amino acids
mutagenesis
mutants
Prior art date
Application number
AT91908402T
Other languages
English (en)
Inventor
Roberto Crea
Original Assignee
Roberto Crea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Crea filed Critical Roberto Crea
Application granted granted Critical
Publication of ATE126535T1 publication Critical patent/ATE126535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Arc Welding In General (AREA)
  • Arc Welding Control (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Confectionery (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT91908402T 1990-04-05 1991-04-05 ''walk-through''-mutagenese. ATE126535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50531490A 1990-04-05 1990-04-05

Publications (1)

Publication Number Publication Date
ATE126535T1 true ATE126535T1 (de) 1995-09-15

Family

ID=24009833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908402T ATE126535T1 (de) 1990-04-05 1991-04-05 ''walk-through''-mutagenese.

Country Status (8)

Country Link
US (3) US5798208A (de)
EP (1) EP0527809B1 (de)
JP (2) JP4251406B2 (de)
AT (1) ATE126535T1 (de)
CA (1) CA2079802C (de)
DE (1) DE69112207T2 (de)
ES (1) ES2078518T3 (de)
WO (1) WO1991015581A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194807A1 (en) * 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
JPH08511417A (ja) * 1993-04-09 1996-12-03 カタリティック アンティボディーズ，インコーポレイテッド 触媒抗体をコードする遺伝子の選択
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5602021A (en) * 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
WO2000053744A2 (en) * 1999-03-09 2000-09-14 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
DE69720043T2 (de) * 1996-12-20 2003-10-16 Unilever N.V., Rotterdam Enzymatische bleichmittelzusammensetzung
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
DE19731990A1 (de) * 1997-07-25 1999-01-28 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung und Identifizierung von neuen Hydrolasen mit verbesserten Eigenschaften
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU2346199A (en) * 1998-01-30 1999-08-16 Sepracor, Inc. Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted thereagainst
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
MXPA00009723A (es) * 1999-02-04 2003-09-22 Diversa Corp Generacion no estocastica de vacunas y enzimas geneticas.
JP3399518B2 (ja) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション 半導体構造およびその製造方法
US6251604B1 (en) 1999-08-13 2001-06-26 Genopsys, Inc. Random mutagenesis and amplification of nucleic acid
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
AU2001241939A1 (en) * 2000-02-28 2001-09-12 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
EP1276861A2 (de) * 2000-03-24 2003-01-22 Maxygen, Inc. Methoden zur modulation zellulärer und organismenspezifischer phenotypen
ES2531551T3 (es) * 2000-04-17 2015-03-17 Dyax Corp. Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
JP2003536075A (ja) * 2000-06-08 2003-12-02 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｃ反応性タンパク質誘導性炎症のインヒビター
FR2813314B1 (fr) * 2000-08-25 2004-05-07 Biomethodes Procede de mutagenese dirigee massive
WO2005012515A2 (en) 2003-04-29 2005-02-10 Pioneer Hi-Bred International, Inc. Novel glyphosate-n-acetyltransferase (gat) genes
US6958213B2 (en) * 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
JP2004532038A (ja) * 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20040096826A1 (en) * 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030199068A1 (en) * 2002-03-05 2003-10-23 Bott Richard R. High throughput mutagenesis screening method
US20030171543A1 (en) * 2002-03-05 2003-09-11 Bott Richard R. High throughput mutagenesis screening method
CA2482863A1 (en) * 2002-04-17 2003-10-30 Roberto Crea Universal libraries for immunoglobulins
WO2003089671A1 (en) * 2002-04-17 2003-10-30 Roberto Crea 'doping' in walk-through mutagenesis
ATE356871T1 (de) 2002-05-17 2007-04-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
AU2003304275A1 (en) 2002-08-06 2005-01-21 Pioneer Hi-Bred International, Inc. Ap1 amine oxidase variants
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE602004027714D1 (de) 2003-04-02 2010-07-29 Univ Texas Anti-tumor effekt von bik-mutanten
US20050136428A1 (en) * 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
EP1781680B8 (de) 2004-07-06 2016-05-18 Bioren, LLC Universelle antikörperbibliotheken
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
EP1933857A2 (de) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemische behandlung von metastasierten und/oder systemisch dissemierten tumoren mit gm-csf-exprimierenden pockenviren
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US20080108513A1 (en) * 2006-06-01 2008-05-08 Northwestern University Cellular Arrays
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2009016433A2 (en) 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
EP2087096A4 (de) * 2006-10-20 2009-11-25 Univ Arizona Modifizierte cyanobakterien
EP2118281A2 (de) * 2007-02-12 2009-11-18 Codexis, Inc. Struktur-wirkungs-beziehungen
US20100106585A1 (en) * 2007-04-17 2010-04-29 American Express Travel Related Services Company, Inc. System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
PT2281078E (pt) * 2008-04-24 2015-02-05 Dyax Corp Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
WO2010111707A1 (en) 2009-03-27 2010-09-30 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
CA2805941A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2718427B1 (de) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Zusammensetzungen zur behandlung von glioblastomen
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
CA2904537A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
EP2970995A1 (de) 2013-03-14 2016-01-20 Pioneer Hi-Bred International, Inc. Zusammensetzungen mit dicamba-decarboxylaseaktivität und verfahren zur verwendung
WO2015089080A2 (en) 2013-12-09 2015-06-18 Adimab, Llc Polyclonal mixtures of antibodies, and methods of making and using them
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
EP3280444B1 (de) 2015-04-10 2024-05-08 Adimab, LLC Verfahren zur reinigung heterodimerer multispezifischer antikörper aus elterlichen homodimeren antikörperarten
EP3297661B1 (de) 2015-05-21 2021-06-30 Full Spectrum Genetics, Inc. Verfahren zur verbesserung der eigenschaften von proteinen
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
WO2018237323A1 (en) 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains
WO2019118918A1 (en) 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130597A (ja) * 1984-07-20 1986-02-12 Nippon Zeon Co Ltd ポリヌクレオチド合成装置
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
WO1989010933A1 (en) * 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68927933T2 (de) * 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
FI87028C (fi) * 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd Metod foer att reglera effekt hos en spaenningsstyrd effektfoerstaerkare och koppling foer anvaendning i metoden
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons

Also Published As

Publication number Publication date
AU7741891A (en) 1991-10-30
US5830650A (en) 1998-11-03
ES2078518T3 (es) 1995-12-16
JPH05506580A (ja) 1993-09-30
CA2079802C (en) 2001-09-18
WO1991015581A1 (en) 1991-10-17
JP2003135084A (ja) 2003-05-13
AU653152B2 (en) 1994-09-22
DE69112207D1 (en) 1995-09-21
JP4275922B2 (ja) 2009-06-10
JP4251406B2 (ja) 2009-04-08
EP0527809A1 (de) 1993-02-24
EP0527809B1 (de) 1995-08-16
DE69112207T2 (de) 1996-03-28
CA2079802A1 (en) 1991-10-06
US6649340B1 (en) 2003-11-18
US5798208A (en) 1998-08-25

Similar Documents

Publication Publication Date Title
DE69112207D1 (en) "walk-through"-mutagenese.
BRPI0412007A (pt) mutagênese look-through
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
NO973848D0 (no) Fremgangsmåte til fremstilling av hemoglobinliknende protein
NO913186L (no) Fremgangsmaate for anvendelse og syntese av peptider.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
AT399720B (de) Gewinnung von amphiregulin durch gentechnische verfahren
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
FI864654A0 (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
ATE121752T1 (de) Entfernung von protein a aus antikörper- präparationen.
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
SE8801701D0 (sv) Production technology based on enzymic method
ES2109225T3 (es) Anticuerpos, su produccion y uso.
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
DK0658626T3 (da) Fremgangsmåder til produktion af protein C
DK0876610T3 (da) Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet
ATE270333T1 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
NO891713D0 (no) Monoklonale antistoffer til vevplasminogenaktivator (t-pa)
Righetti et al. Charge heterogeneity of recombinant pro-urokinase and urinary urokinase, as revealed by isoelectric focusing in immobilized pH gradients
CA2004387A1 (en) Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
KR900007299A (ko) 고농도배양에 의한 단세포단백질의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time